Chunyu Doctor's Evolution to Service-Oriented Pharmaceutical E-commerce: Logic, Challenges, and Future Outlook

Yesterday, Chunyu Yisheng announced its new strategic direction: service-oriented pharmaceutical e-commerce. The core logic is to leverage the service advantages of Chunyu’s online consultation platform to build “strong” and “long-term” relationships with users, thereby creating a new model of pharmaceutical e-commerce premised on services. Breaking away from the traditional traffic-centric e-commerce model, Chunyu aims to transition from providing “a single pill” to delivering “lifelong medication management.” Accordingly, Chunyu will launch its Series D financing round and plans to conduct an initial public offering (IPO) in 2017.

As Rui Ge’s image as a thinker becomes increasingly entrenched in public consciousness, VCBeat must acknowledge that Chunyu’s new strategy is highly innovative. The transition from traffic-driven e-commerce to service-oriented e-commerce indeed aligns with the principles of evolution. Nevertheless, the path of evolution is fraught with challenges. This new route presents Chunyu with several thorny issues that require viable solutions. In brief, these can be summarized into two difficult questions: 1. How can Chunyu navigate this path to make pharmaceutical e-commerce a smoother journey? 2. How should Chunyu design a logical framework that is service-oriented yet still aims at product sales?

How Can We Make the Path for Pharmaceutical E-commerce Easier?

First, whether it is services or traffic, since both are categorized as pharmaceutical e-commerce, they must address the challenges inherent to this sector, including qualifications for online drug sales, qualifications for online prescription drug sales, integration into the medical insurance reimbursement system, and pharmaceutical logistics, among others.

In 2014, Chunyu attempted a drug-sales monetization model through strategic collaboration by integrating the Haoyaoshi online pharmacy into its online consultation platform and promoting it to users. At that time, Chunyu still served as a traffic entry point, acting as a customer acquisition channel for pharmaceutical e-commerce. We certainly do not consider this integration model to be pharmaceutical e-commerce; rather, Chunyu was merely providing a platform for drug resellers.

Clearly, by 2015, Chunyu Yisheng was no longer content to remain within this grafted business model. As it resolved to formally enter the ranks of pharmaceutical e-commerce, it immediately had to confront the industry norms, regulatory restrictions, entry barriers, and competition that came with it.

Certainly, Chunyu Yisheng’s decision was undoubtedly made after carefully weighing the future prospects and barriers of both online consultation and pharmaceutical e-commerce, calculating the pros and cons. Behind this, those of us observing from the sidelines can vaguely understand—it seems that relying solely on selling services may not truly be profitable!

Although Chunyu entered the e-commerce sector by offering services, and its proposed service-oriented e-commerce model is considered innovative in the pharmaceutical e-commerce industry, other pharmaceutical e-commerce companies can still replicate this approach in reverse by integrating services into their platforms. Chunyu cites Walgreens, a well-known US pharmacy chain, as an example; Walgreens has added numerous services—such as medication reminders, health check-ups, and home emergency care—to enhance added value and attract loyal customers, achieving notable success. While Chunyu can emulate this model, other pharmaceutical e-commerce players face few, if any, significant barriers to adoption, and may even find it more straightforward to implement. In fact, Jianyi Online Pharmacy has already launched “Jianyi Doctor,” a doctor-patient communication platform.

It is worth analyzing how the transition from healthcare and medical consulting services to e-commerce differs from the reverse path, i.e., from e-commerce to healthcare and medical consulting services.

The former is a healthcare consulting service platform whose primary revenue source is drug sales. It first provides consulting services and then guides you to purchase products; the more you buy, the greater the benefit to the service provider. Under this model, would you trust such a service?

The latter is a pharmacy that primarily sells medications while also providing additional value-added services. You have the need to purchase drugs, and by choosing to buy here, you can access some extra services, while still retaining autonomy over drug procurement. For patients, even if these services may not be suitable for me, at least there will be no loss.

If the final impression left on consumers is as described, Chunyu clearly has little chance of success. This raises the second question: How should Chunyu design a logic architecture that is service-oriented yet aimed at product sales?

How Does Chunyu Design a Logic Architecture That Is Service-Oriented Yet Aimed at Product Sales?

The core of the service e-commerce model proposed by Chunyu lies in building “strong” and “long-term” relationships between service providers and users, which cannot be sustained by merely entering the online pharmacy market. A new, service-oriented, end-to-end solution must be designed.

When it comes to service-oriented, end-to-end solutions, IBM is a quintessential example. IBM provides IT strategic consulting services to enterprise-level clients, while also selling software and outsourcing services, and ultimately marketing large-scale hardware equipment. This carefully crafted, service-oriented, end-to-end solution by IBM is undoubtedly a paradigm of “strong relationships” and “long-term relationships.” However, when examining IBM’s profit margins across its three major segments—consulting services, software, and hardware—hardware generates the highest profits, followed by software, with consulting yielding the lowest. Although consulting appears to be the most high-end offering, it actually has the thinnest profit margins; in reality, the true mission of this segment is to serve as a funnel for subsequent software and hardware sales.

This logic appears strikingly similar to that of Chunyu, yet the underlying premises are entirely different. From consulting services to software and then to hardware, IBM sells only its own products, and this end-to-end solution is fully controlled by IBM. In other words, by adopting IBM’s entire suite, you may not gain additional benefits, but you can at least ensure optimal integration and compatibility. This is precisely the greatest advantage of an end-to-end solution over fragmented individual services or products.

This raises the question: What kind of end-to-end solution should Chunyu Design to demonstrate its unique advantages? Since neither the services nor the products can be considered proprietary to Chunyu, what advantages do users gain by purchasing bundled packages from Chunyu rather than procuring them separately? Is there a suspicion that Chunyu’s product bundles are designed to promote and tie-in unnecessary products solely to boost profits? No matter how “strong” the relationship appears, it remains fundamentally one between a service provider and a client, involving direct financial transactions. Such “strength” is only relative, and its actual influence remains to be verified.

In the past, healthcare system reforms have frequently called for the separation of prescribing and dispensing. Under this model, physicians diagnose and prescribe medications, but the revenue from patients’ medication purchases is decoupled from the hospitals where these physicians practice, thereby curbing the tendency of doctors to overprescribe or inappropriately prescribe drugs to boost pharmaceutical sales. This issue is further compounded by the widespread practice of numerous pharmaceutical companies using physicians as sales channels and engaging in substantial bribery. Chunyu needs to design a new model that enables the complete process of diagnosis and prescription while clearly delineating and disentangling the complex financial interests between physicians and drug sales.

Chunyu’s Icebreaking Strategy: Data Is the Core

Chunyu Doctor, which currently lacks various licenses for pharmaceutical e-commerce, has entered the e-commerce sector by focusing on infant and toddler products. The “Chunyu Mommy Box,” a parenting package priced at 998 yuan that includes 12 months of parenting consultation services, is now on sale. Beyond the consultation services themselves, the Chunyu Parenting Package ultimately hinges on which products are sold. According to Chunyu, product selection for the Mommy Box is data-driven, based on insights accumulated from its online parenting consultation services—specifically, products that have been frequently mentioned by mothers and relatively more endorsed by doctors.

Based on this logic, the model essentially enables users to select products, which are then endorsed by professionals, with Chunyu ultimately handling the procurement. This represents a shift from the traditional approach of pushing products to users toward a model that assists users in selecting and purchasing products. This is what Chunyu refers to as the C2B (Consumer-to-Business) model. While individual users lack decision-making authority over product content, they collectively exercise such authority as a group, effectively achieving an optimized form of decision-making power.

It can be said that the model design of Chunyu’s Parenting Care Package has, to a certain extent, resolved the second issue we previously raised: the logical architecture that is service-oriented yet aims at product sales. The only aspect requiring further in-depth exploration is the transparency and credibility of the data sources underlying the selection of products within the Parenting Care Package—that is, how Chunyu can convince users that these choices reflect their own preferences rather than being imposed by Chunyu.

The parenting sector is relatively straightforward, as most infants and toddlers exhibit similar growth patterns and consistent needs, making it easier to mine user preferences from historical data and evaluate product quality. However, extending this approach to the chronic disease management sector that Chunyu aims to develop could become significantly more complex. As previously mentioned, challenges include how to achieve the separation of prescribing and dispensing on service-oriented e-commerce platforms and how to prevent physicians from writing excessive prescriptions. With the backing of data and precise algorithms, it would be possible to better curb physicians’ impulse to prescribe costly medications.

Extracting credible and accurate information from data, and designing chronic disease management packages for patients with vastly different conditions, is indeed a challenging task. However, it is precisely this difficulty that creates a competitive barrier, and the data accumulated by Chunyu over the past four years has truly proven valuable in building its moat.

How Can Pharmaceutical E-Commerce Become an Easier Path? By Leveraging Four Years of Accumulated Doctor-Patient Communication Data, a Resource Unavailable to Other E-Commerce Platforms. Only by fully unlocking the value of Chunyu’s four-year data accumulation can it truly emerge from the currently fierce competition in the pharmaceutical e-commerce sector.

VCBeat believes that, in fact, whether the core focus is “service” or “traffic” is not the essence of this game; the crux lies in the collection, mastery, and exploitation of user value data. In the future, Chunyu can not only engage in e-commerce but also evolve into a platform-based organization, serving as the data access point for every niche segment within the healthcare field, and leveraging this foothold to incubate and foster a vast ecosystem. Perhaps Chunyu is already preparing to incubate a batch of hardware and software startups—isn’t this exactly what Xiaomi has done?

Read more articles by this authorGu Beini Column